XML 28 R19.htm IDEA: XBRL DOCUMENT v3.26.1

Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2026

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

11. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

		June 30, 2026				December 31, 2025
Product revenue allowances		$	11,115			$	9,810
Accrued clinical study and trial costs			20,878				18,977
Accrued selling, general, and administrative costs			6,483				6,316
Accrued compensation and related costs			11,384				24,352
Accrued milestone costs			—				10,000
Accrued royalty payable			8,183				7,372
Accrued interest - royalty interest financing			34,149				25,516
Accrued interest - convertible note			555				—
Other			1,550				721
Total accrued expenses and other current liabilities		$	94,297			$	103,064

X

- Definition

The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483384/720-30-45-1

+ Details

Name:	us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration